The obesity epidemic is closely associated with the rising prevalence and severity of
nonalcoholic fatty liver disease (NAFLD): obesity has been linked not only with simple …

Nonalcoholic fatty liver disease (NAFLD) is estimated to afflict approximately 1 billion
individuals worldwide. In a subset of NAFLD patients, who have the progressive form of …

The correct identification of patients at increased risk of non-alcoholic steatohepatitis
(NASH) and advanced fibrosis is a critical step in the assessment of non-alcoholic fatty liver …

Background & Aims The enhanced liver fibrosis (ELF) test has been proposed for the non-
invasive assessment of advanced fibrosis in patients with non-alcoholic fatty liver disease …

Nonalcoholic fatty liver disease (NAFLD) is a spectrum comprised of isolated steatosis,
nonalcoholic steatohepatitis (NASH), advanced fibrosis, and cirrhosis. The majority of …

The pathophysiology of NAFL and NASH is complex and numerous intermediaries are
involved. Each year brings new and exciting developments as pieces of the …

Non-alcoholic steatohepatitis (NASH) is part of the spectrum of non-alcoholic fatty liver
disease (NAFLD) that leads to progressive liver disease and presents a growing challenge …

Nonalcoholic steatohepatitis (NASH) is a leading cause of liver disease worldwide.
However, the molecular basis of how benign steatosis progresses to NASH is incompletely …

Nonalcoholic fatty liver disease (NAFLD) encompasses a spectrum of liver disorders
characterized by abnormal hepatic fat accumulation, inflammation, and hepatocyte …

Since the discovery of adipose tissue as a higly active endocrine tissue, adipokines,
peptides produced by adipose tissue and exerting autocrine, paracrine and endocrine …